Valganciclovir is effective prophylaxis for CMV in high risk renal transplant recipients.

被引：0
|
作者：
Baillie, GM [1 ]
Ashcraft, EE [1 ]
Taber, DJ [1 ]
Stone, SS [1 ]
Emovon, O [1 ]
Rogers, J [1 ]
Afzal, F [1 ]
Lin, A [1 ]
Rajagopalan, PR [1 ]
Baliga, PK [1 ]
Chavin, KD [1 ]
机构：
[1] Med Univ S Carolina, Div Transplant Surg, Charleston, SC 29425 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：377A / 377A
页数：1
相关论文
共 50 条
  • [21] Standard versus Reduced-Dose Valganciclovir CMV Prophylaxis in High-Risk Liver Transplant Recipients
    Dann, J.
    Geyston, J.
    Majmundar, D.
    Haywood, S.
    Shoemaker, C.
    Pelletier, S.
    Wentworth, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (06) : S395 - S395
  • [22] A unique 6-week course of oral valganciclovir for CMV infection in adult renal transplant recipients.
    Smith, LD
    Aggers, P
    Shihab, F
    PHARMACOTHERAPY, 2005, 25 (03): : 475 - 475
  • [23] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Rumore, A.
    Brueckner, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S115 - S116
  • [24] CMV Viremia after Discontinuation of Valganciclovir Prophylaxis in Lung Transplant Recipients
    Gift, T.
    Palafox, J.
    Jones, K.
    Imburgia, T.
    Astor, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S485 - S485
  • [25] Cytomegalovirus immune globulin therapy for CMV prophylaxis in high-risk renal allograft recipients.
    Amenábar, JJ
    Muñiz, ML
    Martínez, MP
    Bilbao, J
    Figuero, MP
    Gómez-Ullate, P
    Lampreabe, I
    KIDNEY INTERNATIONAL, 1999, 55 (01) : 369 - 369
  • [26] A prospective assessment of valganciclovir for the treatment of cytomegalovirus (CMV) infection and disease in transplant recipients.
    Humar, A
    Moussa, G
    Mazzulli, T
    Siegal, D
    Kumar, D
    AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 385 - 385
  • [27] Extended Valganciclovir Prophylaxis Is Well Tolerated in Pediatric Kidney Transplant Recipients.
    Benchimol, C.
    Tedesco Silva, H., Jr.
    Varela-Fascinetto, G.
    Genevray, M.
    Bradley, D.
    Ives, J.
    TRANSPLANTATION, 2014, 98 : 497 - 497
  • [28] Ganciclovir prophylaxis is more effective than intravenous immunoglobulin (IVIG) in preventing cytomegalovirus (CMV) disease in renal transplant recipients.
    Sankari, BR
    Wyner, LM
    Walton, T
    Claridades, D
    VanWyck, C
    JOURNAL OF UROLOGY, 1998, 159 (05): : 185 - 185
  • [29] Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients
    Fayek, Sameh Adel
    Mantipisitkul, Wana
    Rasetto, Flavia
    Munivenkatappa, Raghava
    Barth, Rolf N.
    Philosophe, Benjamin
    HPB, 2010, 12 (10) : 657 - 663
  • [30] Efficacy of valganciclovir plus cytomegalovirus immune globulin for prevention of cytomegalovirus disease in high risk renal transplant recipients.
    Bitterman, Amanda N.
    Maldonado, Angela Q.
    Ojogho, Okechukwu N.
    Siegel, Ruby
    Weeks, Douglas L.
    PHARMACOTHERAPY, 2012, 32 (10): : E305 - E305
12345